Higher risk of type 2 diabetes in women with hyperandrogenic polycystic ovary syndrome

Objective To assess the risk of type 2 diabetes (T2D) in women with polycystic ovary syndrome (PCOS) relation to body mass index (BMI) and hyperandrogenic (HA) PCOS phenotype. Design Population-based cohort study. Setting Data from six Swedish national registers, participants being followed for a maximum 19 years. Patient(s) All an International Statistical Classification Diseases Related Health Problems, version 10, diagnosis PCOS, androgen excess, or anovulatory infertility born between 1950 1999 (n = 52,535) were identified Patient Register. The HA phenotype was defined by two filled prescriptions anti-androgenic drugs. For each woman five control 254,624) randomly chosen Total Population Register, matched age geographic area. Intervention(s) No interventions performed. Main Outcome Measure(s) T2D prescription antidiabetic treatment other than metformin. Result(s) cumulative incidence rates 1.3%, 4.4%, 14.2% controls (non-PCOS women) normoandrogenic (NA) respectively. After adjustment BMI, had twofold higher rate non-PCOS (adjusted hazard ratio, 2.52 [95% confidence interval, 2.15–2.96]). Women those NA 3.86 3.16–4.72]). Conclusion(s) Polycystic is independent factor T2D, even after BMI. face